Sun Pharma Q1 net rises over 3-fold to Rs 2,034 cr
16/08/2016 12:24
NIFTY Fut : Trend : SELL ZONE
Click Here & Register To Get 2 days Trial Tips
Free Intraday Tips : Join Our Whatsapp No : 9841986753
Indian multinational pharmaceutical major Sun Pharmaceutical Industries Ltd has reported that its consolidated net profit for the first quarter ended June 30, 2016 jumped more than three-fold to Rs 2,033.71 crore driven by higher sales amidst impressive growth in its top market, the US, which makes up half of its revenue.
In Q1 FY 2015-16, the company had posted a consolidated net profit of Rs 556 crore, Sun Pharmaceutical Industries Ltd said in a filing to the Bombay Stock Exchange (BSE).
Consolidated total income from operations climbed 22 per cent at Rs 8,243 crore in Q1 FY 2016-17 from Rs 6,761.5 crore in the same period a year ago.
Consolidated total expenses rose 7.7 per cent at Rs 5,638 crore in Q1 FY 2016-17 from Rs 5,234 crore in the same period a year ago.
Consolidated other income fell by 4.3 per cent at Rs 157.1 crore in Q1 FY 2016-17 from Rs 164.11 crore in the same period a year ago.
Consolidated finance costs were flat at Rs 134.62 crore in Q1 FY 2016-17.
The company’s financials in Q1 FY 2015-16 were hit by one off costs and exceptional items of Rs 685 crore related to the Ranbaxy integration.
Shares of the company tumbled 1.46 per cent to Rs 790.10 a piece at 12:22 PM IST on Tuesday on the BSE.
16/08/2016 12:24
NIFTY Fut : Trend : SELL ZONE
Free Intraday Tips : Join Our Whatsapp No : 9841986753
Indian multinational pharmaceutical major Sun Pharmaceutical Industries Ltd has reported that its consolidated net profit for the first quarter ended June 30, 2016 jumped more than three-fold to Rs 2,033.71 crore driven by higher sales amidst impressive growth in its top market, the US, which makes up half of its revenue.
In Q1 FY 2015-16, the company had posted a consolidated net profit of Rs 556 crore, Sun Pharmaceutical Industries Ltd said in a filing to the Bombay Stock Exchange (BSE).
Consolidated total income from operations climbed 22 per cent at Rs 8,243 crore in Q1 FY 2016-17 from Rs 6,761.5 crore in the same period a year ago.
Consolidated total expenses rose 7.7 per cent at Rs 5,638 crore in Q1 FY 2016-17 from Rs 5,234 crore in the same period a year ago.
Consolidated other income fell by 4.3 per cent at Rs 157.1 crore in Q1 FY 2016-17 from Rs 164.11 crore in the same period a year ago.
Consolidated finance costs were flat at Rs 134.62 crore in Q1 FY 2016-17.
The company’s financials in Q1 FY 2015-16 were hit by one off costs and exceptional items of Rs 685 crore related to the Ranbaxy integration.
Shares of the company tumbled 1.46 per cent to Rs 790.10 a piece at 12:22 PM IST on Tuesday on the BSE.
